Please login to the form below

Not currently logged in
Email:
Password:

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.

Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.

Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.

Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.

“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”

Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.

Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.

4th February 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics